ArticleEye (London, England)2026
Outcomes of phacoemulsification combined with ab interno trabeculotomy: stratified by incision extent, glaucoma severity, and baseline number of medications.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate outcomes of phacoemulsification plus Tanito microhook (TMH) trabeculotomy and assess differences by incision extent, glaucoma severity, and baseline medications classes.
methodsRetrospective cohort of 880 open-angle glaucoma eyes (119 exfoliation glaucoma, 761 primary open-angle glaucoma) undergoing phaco-TMH. Success was defined using the American Academy of Ophthalmology (AAO) minimally invasive glaucoma surgery (MIGS) endpoint for cataract-combined procedures ( ≥ 1 medication reduction without intraocular pressure [IOP] increase, or ≥20% IOP reduction to ≤21 mmHg) with no additional glaucoma surgery, hypotony, or loss of light perception. Prespecified alternative IOP-defined success definitions were also evaluated. Outcomes were stratified by incision extent ( < 6 and ≥6 clock hours), baseline glaucoma severity (early, moderate, advanced), and baseline medications classes (0-1, 2, ≥3). Time-to-failure was evaluated using Kaplan-Meier analysis and multivariable Cox proportional hazards models adjusted for surgical year and baseline covariates.
resultsMean (SD) IOP decreased from 17.2 (4.9) mmHg at baseline to 13.1 (3.5) at 12 months and 13.1 (3.9) at 24 months, and medications decreased from 2.6 (1.3) to 2.0 (1.3) at 12 and 24 months. Two-year cumulative success was 59.0% (95% CI, 54.4 to 63.2) by AAO MIGS criteria. In the multivariable Cox model, ≥6 clock hours was not significantly associated with surgical failure compared with <6 clock hours (adjusted HR, 1.14; 95% CI, 0.85 to 1.53; P = 0.367). Higher baseline medication burden was associated with worse success across IOP-defined criteria.
conclusionsIn patients undergoing phacoemulsification combined with TMH trabeculotomy, IOP and medication burden improved through 2 years. Surgical success did not differ by incision extent or baseline glaucoma severity, whereas higher baseline medication burden was associated with worse IOP-defined success.
Identifiers
42487033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.